Scopolamine api market?

Market Overview and Patent Information

The Scopolamine API (Active Pharmaceutical Ingredient) market has several patents and manufacturers involved. According to DrugPatentWatch.com [1], Scopolamine is protected by U.S. Patent No. 6,441,190, which expires in 2025 [1]. This patent covers a method for preparing a Scopolamine hydrobromide formulation.

Manufacturers and Global Market

Several manufacturers produce Scopolamine API, including Mylan N.V., AstraZeneca, and various Asian firms such as Anhui Anke Biotechnology (Group) Co., Ltd. and Chongqing Kanger Pharmaceutical Co., Ltd. [2]. The global Scopolamine API market is influenced by the presence of generics and biosimilars, which can alter the competitive landscape.

Generic and Biosimilar Scopolamine

Several generic and biosimilar Scopolamine products have entered the market, often at lower prices than branded versions. These entrants may face regulatory scrutiny due to concerns about the biosimilar manufacturing process. Companies like Teva Pharmaceutical Industries Ltd. have developed Scopolamine generics that adhere to strict regulatory standards for biosimilarity [3].

Price Pressure and Market Dynamics

Price competition from generics and biosimilars has placed downward pressure on the market prices of Scopolamine API. As new entrants join the market, manufacturers are forced to navigate this increasingly competitive environment. Market share shifts and pricing trends may favor the more aggressive pricing strategies of the new entrants.

Timeline of Key Events and Patent Expiration

The current patent for Scopolamine expires in 2025. As the market evolves in the lead-up to patent expiration, expect increased market competition and the emergence of additional manufacturers.

Sources
[1] DrugPatentWatch.com - U.S. Patent No. 6,441,190.
[2] Various sources - Manufacturers of Scopolamine API.
[3] Teva Pharmaceutical Industries Ltd. - Development of Scopolamine generics.